ARS Pharmaceuticals, Inc.
SPRY
$8.25
-$0.05-0.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -171.30M | -80.04M | -48.02M | -15.65M | 8.00M |
| Total Depreciation and Amortization | 1.37M | 979.00K | 609.00K | 348.00K | 79.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.07M | 16.90M | 13.89M | 9.28M | 7.28M |
| Change in Net Operating Assets | -20.00M | -23.22M | -19.27M | -14.46M | -1.81M |
| Cash from Operations | -170.87M | -85.38M | -52.80M | -20.48M | 13.55M |
| Capital Expenditure | -339.00K | -641.00K | -584.00K | -571.00K | -563.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 57.11M | -68.47M | -6.72M | -67.95M | -105.54M |
| Cash from Investing | 56.77M | -69.11M | -7.31M | -68.52M | -106.10M |
| Total Debt Issued | 96.26M | 97.75M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.68M | 5.43M | 5.64M | 3.48M | 3.02M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.66M | 71.20M | 69.38M | 69.38M | 69.38M |
| Cash from Financing | 104.60M | 174.38M | 75.02M | 72.87M | 72.40M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.50M | 19.90M | 14.91M | -16.14M | -20.15M |